Table 1 Survivor characteristics
All (N = 337) | Missing data | Training cohort (n = 237) | Test cohort (n = 100) | p-value (Welch t-test) | |
|---|---|---|---|---|---|
Median age at survey, years (range) | 62 (31–86) | 0 | 62 (35–83) | 62 (31-86) | 0.922 |
Treatment N (%) | |||||
Docetaxel | 177 (52.5%) | 0 | 132 (55.7%) | 45 (45.0%) | 0.074 |
Paclitaxel | 150 (44.5%) | 0 | 97 (40.9%) | 53 (53.0%) | 0.044 |
Both | 10 (3.0%) | 0 | 8 (3.4%) | 2 (2.0%) | 0.454 |
Mean dose mg/m2 (SD) | |||||
Paclitaxel | 842.4 (190.0) | 0 | 833.0 (197) | 860.4 (176.5) | 0.044 |
Docetaxel | 263.3 (60.5) | 0 | 260.7 (66.9) | 271.0 (34.4) | 0.123 |
Mean BMI kg/m2 at survey (SD) | 26.9 (4.7) | 0 | 27.2 (4.6) | 26.1 (4.7) | 0.063 |
Treatment for diabetes mellitus N (%) | 16 (4.7%) | 0 | 11 (4.6%) | 5 (5.0%) | 0.890 |
Mean years from taxane to survey, (SD) | 4.0 (1.5) | 0 | 4.1 (1.6) | 3.8 (1.5) | 0.926 |
Proportion with moderate to severe taxane-induced peripheral neuropathy symptoms N (%) | |||||
Cramps in feet | 93 (27.6%) | 2 (0.6%) | 72 (30.1%) | 21 (21.0%) | 0.066 |
Difficulty opening a jar | 88 (26.1%) | 0 | 58 (24.5%) | 30 (30.0%) | 0.306 |
Numbness in feet | 86 (25.5%) | 2 (0.6%) | 61 (25.7%) | 25 (25.0%) | 0.887 |
Tingling in feet | 83 (24.6%) | 2 (0.6%) | 63 (26.6%) | 20 (20.0%) | 0.184 |
Difficulty climbing stairs | 41 (12.1%) | 0 | 28 (11.8%) | 13 (13.0%) | 0.766 |
